SG11202107941TA - Cd31 competitors and uses thereof - Google Patents

Cd31 competitors and uses thereof

Info

Publication number
SG11202107941TA
SG11202107941TA SG11202107941TA SG11202107941TA SG11202107941TA SG 11202107941T A SG11202107941T A SG 11202107941TA SG 11202107941T A SG11202107941T A SG 11202107941TA SG 11202107941T A SG11202107941T A SG 11202107941TA SG 11202107941T A SG11202107941T A SG 11202107941TA
Authority
SG
Singapore
Prior art keywords
competitors
Prior art date
Application number
SG11202107941TA
Inventor
Laurence Bressac
Serge Guerreiro
Damien Toulorge
Original Assignee
Encefa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encefa filed Critical Encefa
Publication of SG11202107941TA publication Critical patent/SG11202107941TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
SG11202107941TA 2019-01-23 2020-01-23 Cd31 competitors and uses thereof SG11202107941TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305086 2019-01-23
PCT/EP2020/051667 WO2020152290A1 (en) 2019-01-23 2020-01-23 Cd31 competitors and uses thereof

Publications (1)

Publication Number Publication Date
SG11202107941TA true SG11202107941TA (en) 2021-08-30

Family

ID=65409014

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107941TA SG11202107941TA (en) 2019-01-23 2020-01-23 Cd31 competitors and uses thereof

Country Status (12)

Country Link
US (1) US20220089765A1 (en)
EP (1) EP3914616A1 (en)
JP (1) JP2022523047A (en)
KR (1) KR20210119448A (en)
CN (1) CN113614107A (en)
AU (1) AU2020211728A1 (en)
CA (1) CA3127520A1 (en)
IL (1) IL284962A (en)
MX (1) MX2021008672A (en)
SG (1) SG11202107941TA (en)
WO (1) WO2020152290A1 (en)
ZA (1) ZA202105154B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3943505A1 (en) 2020-07-22 2022-01-26 Encefa Cd38-binding cd31 peptides and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE139258T1 (en) 1990-01-12 1996-06-15 Cell Genesys Inc GENERATION OF XENOGENE ANTIBODIES
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
DK2270150T4 (en) 1999-04-09 2019-08-26 Kyowa Hakko Kirin Co Ltd PROCEDURE TO CONTROL THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE.
FR2807767B1 (en) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement MONOCLONAL ANTIBODIES ANTI-D
DE60131456T2 (en) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas TRANCHROMOSOMAL TRANSGEN RODENTS FOR THE MANUFACTURE OF HUMAN ANTIBODIES
PT1355919E (en) 2000-12-12 2011-03-02 Medimmune Llc Molecules with extended half-lives, compositions and uses thereof
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
EP2364996B1 (en) 2002-09-27 2016-11-09 Xencor Inc. Optimized FC variants and methods for their generation
JP2006524039A (en) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド Identification and production of antibody containing mutant Fc region and use thereof
CN106434683B (en) * 2005-10-12 2020-03-13 莫佛塞斯公司 Generation and characterization of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
DK2388273T3 (en) 2005-10-21 2017-10-09 Lfb Usa Inc ANTIBODIES WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, PROCEDURES FOR THE PRODUCTION OF THESE AND USE THEREOF
ATE542830T1 (en) 2006-12-04 2012-02-15 Pasteur Institut OB-FOLD USED AS A SCAFFOLD FOR THE DEVELOPMENT OF NEW SPECIFIC BINDERS
HUE037302T2 (en) 2007-06-01 2018-08-28 Open Monoclonal Tech Inc Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies
KR102100066B1 (en) 2008-10-14 2020-04-10 제넨테크, 인크. Immunoglobulin variants and uses thereof
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
JOP20210044A1 (en) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-cd38 antibodies
FR3003171B1 (en) 2013-03-15 2015-04-10 Lab Francais Du Fractionnement NOVEL MEDICAMENTS COMPRISING AN ENHANCED ANTIBODY COMPOSITION IN MAJORITY LOAD ENFORCEMENT
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
MA40894A (en) 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa HETERODIMERIC IMMUNOGLOBULINS RE-TARGET CD3 / CD38 T-LYMPHOCYTES AND THEIR PRODUCTION PROCESSES
TWI787942B (en) 2015-06-24 2022-12-21 日商Ｊｃｒ製藥股份有限公司 Anti-human transferrin receptor antibody that passes through blood-brain barrier
CA3066553A1 (en) 2017-06-08 2018-12-13 Black Belt Therapeutics Limited Cd38 modulating antibody

Also Published As

Publication number Publication date
CN113614107A (en) 2021-11-05
WO2020152290A1 (en) 2020-07-30
CA3127520A1 (en) 2020-07-30
EP3914616A1 (en) 2021-12-01
ZA202105154B (en) 2023-01-25
AU2020211728A1 (en) 2021-08-12
KR20210119448A (en) 2021-10-05
JP2022523047A (en) 2022-04-21
MX2021008672A (en) 2021-11-03
US20220089765A1 (en) 2022-03-24
IL284962A (en) 2021-09-30

Similar Documents

Publication Publication Date Title
EP4076448A4 (en) Fluoroalkyl-oxadiazoles and uses thereof
IL289585A (en) Dll3-targeting antibodies and uses thereof
IL290141A (en) Anti-pvrig antibodies formulations and uses thereof
ZA202105847B (en) Mtroc modulators and uses thereof
EP4081308A4 (en) Smarca degraders and uses thereof
GB2591554B (en) Composiitons and methods and uses relating thereto
IL287690A (en) Anti-hvem antibodies and use thereof
SG11202112112UA (en) Anti-galectin-9 antibodies and uses thereof
IL291027A (en) Anti-steap1 antibodies and uses thereof
EP4063489A4 (en) Composition and use thereof
IL291546A (en) Anti-kir3dl3 antibodies and uses thereof
IL291550A (en) Anti-il-27 antibodies and uses thereof
IL290301A (en) Il-15 conjugates and uses thereof
GB202201001D0 (en) Polypeptide and use thereof
ZA202105154B (en) Cd31 competitors and uses thereof
IL265486A (en) Bistable type ii opsins and uses thereof
IL289531A (en) Cd38-binding agents and uses thereof
IL288828A (en) Cd38-binding agents and uses thereof
IL290516A (en) Composites and uses thereof
IL291280A (en) Anti-cd371 antibodies and uses thereof
EP4006048A4 (en) Novel micropeptide hmmw and application thereof
IL286803A (en) Anti-tauc3 antibodies and uses thereof
IL285916A (en) Novel compositions and use thereof
GB201906914D0 (en) Substituted naphtahlene diimdes and their use
GB201901413D0 (en) Compositions and their use